SK C&C Co., the information technology (IT) service unit of South Korea’s SK Group, announced Thursday that its artificial intelligence (AI) diagnostic solution for brain infarcts has received a grade 3 medical device approval from the Ministry of Food and Drug Safety in Korea.

The solution, named Medical Insight+ Brain Infarct, leverages independently developed deep learning algorithms, which were trained on imaging data from thousands of patients diagnosed with brain infarcts.

To enhance the AI diagnostic accuracy, validation procedures were conducted by neuro-radiologists from Seoul National University and Ajou University Hospital.

The solution efficiently analyzes non-contrast brain computed tomography (CT) images within seconds to identify any abnormalities.

It provides healthcare professionals with a numerical representation of the likelihood of brain infarction, ranging from zero percent to 100 percent, and categorizes it into seven severity levels for prompt decision-making.

To assist medical professionals further, the solution highlights abnormal areas using a heat map or outlines, ensuring that even subtle regions are easily identifiable.

SK C&C emphasized the complementary use of this brain infarct solution with its previously ministry-approved brain hemorrhage diagnostic AI named Medical Insight+ Brain Hemorrhage.

This simultaneous interpretation of non-contrast CT images allows for the rapid diagnosis of both brain hemorrhages and brain infarcts, significantly reducing the time required for stroke diagnosis.

SK C&C’s AI-driven cerebral hemorrhage diagnosis solution was previously approved as a grade 3 medical device by the MFDS in 2021.

The health authorities categorize medical devices into four classes based on their purpose and potential harm to the human body, with grade 3 devices undergoing thorough evaluations, including clinical trials.

By Pulse

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]